The emergence of various novel therapies over the last decade has changed the therapeutic
landscape for multiple myeloma. While the clinical outcomes have improved significantly …

Summary Here, the International Myeloma Working Group (IMWG) updates its clinical
practice recommendations for the management of multiple myeloma-related renal …

ABSTRACT CD38 is a transmembrane glycoprotein with ectoenzymatic activity and is highly
and uniformly expressed on multiple myeloma (MM) cells. CD38 is expressed also at …

Background Natural killer/T-cell lymphoma (NKTCL) is a disease with limited treatment
options and poor outcomes. Daratumumab monotherapy demonstrated clinical activity in a …

Multiple myeloma (MM) remains an incurable hematological malignancy disease
characterized by the progressive dysfunction of the patient's immune system. In this context …

Significant progress has been achieved in the realm of therapeutic interventions for multiple
myeloma (MM), leading to transformative shifts in its clinical management. While …

In the primary analysis of the phase III COLUMBA study, daratumumab by subcutaneous
administration (DARA SC) demonstrated non-inferiority to intravenous administration (DARA …

Daratumumab is a fully human, monoclonal immunoglobulin G1 and a first-in-class CD38-
targeting drug approved by the US Food and Drug Administration for the treatment of …

Background Adoptive transfer of natural killer (NK) cells with augmented antibody-
dependent cellular cytotoxicity (ADCC) capabilities and resistance to CD38 targeting has the …

Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen receptor T-cell therapy studied in
patients with multiple myeloma exposed to three classes of treatment in the single-arm …